# Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

> **NCT02908477** · PHASE3 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 228 (actual)

## Conditions studied

- Oropharynx Cancer

## Interventions

- **RADIATION:** Adjuvant Radiation Therapy
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02908477
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-03
- **Primary completion:** 2022-08-20
- **Final completion:** 2024-11-15
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02908477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02908477, "Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02908477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*